340B

Manufacturer updates

HRSA Update

On May 17th, 2021, HRSA sent six pharmaceutical manufacturers letters stating that their restriction of 340B pricing to Contract Pharmacies is in direct violation of 340B statute. 

 

Amgen 

Effective January 1st, 2021, Amgen will no longer provide voluntary, “340B like” discounts, on orphan designated drugs to participating Covered Entities.

Contact:
340Brelations@amgen.com

AstraZeneca

Effective October 1st, 2020, AstraZeneca will only provide 340B priced product to a single pharmacy.



Contact: membership@AstraZeneca.com 

Eli Lilly

Effective September 1st, 2020, Lilly restricted access for 340B priced product to Contract Pharmacies, except insulin.


Contact:
340B@lilly.com

Novartis

Effective November 16th, 2020, Novartis will restrict 340B priced product to Contract Pharmacies based on a 40 mile radius for hospital Covered Entities. Federal Grantees not subject to limitations.

Contact: Novartis.340B@novartis.com

Novo Nordisk

Effective January 1st, 2021, Novo Nordisk will restrict 340B priced product to Contract Pharmacies for hospital Covered Entities. Federal Grantees not subject to limitations.


Contact: 340BInfo@novonordisk.com 

Sanofi

Effective October 1st, 2020, Sanofi will only provide 340B priced product to a Contract Pharmacy if Covered Entity provides Claims Level Detail via 340B ESP platform. 


Contact: Sanofi340Boperations@sanofi.com
 

United Therapeutics

Effective May 13th, 2021, United Therapeutics will only provide 340B priced product to a Contract Pharmacy if Covered Entity provides Claims Level Detail via 340B ESP platform. 

Contact:
340B@unither.com